Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes

Cell Stem Cell. 2024 Feb 12:S1934-5909(24)00008-0. doi: 10.1016/j.stem.2024.01.007. Online ahead of print.ABSTRACTAdvances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies.PMID:38366587 | DOI:10.1016/j.stem.2024.01.007

Source: Cell Stem Cell - February 17, 2024 Category: Stem Cells Authors: Kavita Raniga Aishah Nasir Nguyen T N Vo Ravi Vaidyanathan Sarah Dickerson Simon Hilcove Diogo Mosqueira Gary R Mirams Peter Clements Ryan Hicks Amy Pointon Will Stebbeds Jo Francis Chris Denning Source Type: research